EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of newborn screening for SCID on the management of congenital athymia

Evey Howley, Zainab Golwala, Matthew Buckland, Federica Barzaghi, Sujal Ghosh, Scott Hackett, Rosie Hague, Fabian Hauck, Ursula Holzer, Adam Klocperk, Minna Koskenvuo, Nufar Marcus und 14 weitere

Journal of Allergy and Clinical Immunology · 2024-01 · 153 (1) · 330-334

DOI: 10.1016/j.jaci.2023.08.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024-01. Verfasst von Evey Howley und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Gene Therapy, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Immunologic Deficiency Syndromes, Severe Combined Immunodeficiency. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Newborn screening (NBS) programs for severe combined immunodeficiency facilitate early diagnosis of severe combined immunodeficiency and promote early treatment with hematopoietic stem cell transplantation, resulting in improved clinical outcomes. Infants with congenital athymia are also identified through NBS because of severe T-cell lymphopenia. With the expanding introduction of NBS programs, referrals of athymic patients for treatment with thymus transplantation have recently increased at Great Ormond Street Hospital (GOSH) (London, United Kingdom). OBJECTIVE: We studied the impact of NBS on timely diagnosis and treatment of athymic infants with thymus transplantation at GOSH. METHODS: We compared age at referral and complications between athymic infants diagnosed after clinical presentation (n = 25) and infants identified through NBS (n = 19) who were referred for thymus transplantation at GOSH between October 2019 and February 2023. We assessed whether age at time of treatment influences thymic output at 6 and 12 months after transplantation. RESULTS: The infants referred after identification through NBS were significantly younger and had fewer complications, in particular fewer infections. All deaths occurred in the group of those who did not undergo NBS, including 6 patients before and 2 after thymus transplantation because of preexisting infections. In the absence of significant comorbidities or diagnostic uncertainties, timely treatment was achieved more frequently after NBS. Treatment when younger than age 4 months was associated with higher thymic output at 6 and 12 months after transplantation. CONCLUSION: NBS contributes to earlier recognition of congenital athymia, promoting referral of athymic patients for thymus transplantation before they acquire infections or other complications and facilitating treatment at a younger age, thus playing an important role in improving their outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunologic Deficiency SyndromesSevere Combined ImmunodeficiencyNeonatal ScreeningHumansThymus GlandInfant, NewbornInfant

Stichwörter der Autor:innen

DiGeorge syndromeThymus transplantationathymianewborn screeningsevere combined immunodeficiency

Autor:innen und Institutionen

  • Department of Immunology and Gene Therapy, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
  • San Raffaele Telethon Institute for Gene Therapy and Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University, Düsseldorf, Germany.
  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Department of Paediatric Infectious Diseases and Immunology, Royal Hospital for Children, Glasgow, United Kingdom.
  • Department of Pediatrics, Dr von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Zitieren

APA

Howley, E., Golwala, Z., Buckland, M., Barzaghi, F., Ghosh, S., Hackett, S., Hague, R., Hauck, F., Holzer, U., Klocperk, A., Koskenvuo, M., Marcus, N., Marzollo, A., Pac, M., Sinclair, J., Speckmann, C., Soomann, M., Speirs, L., Suresh, S., …, & Kreins, A. Y. (2024). Impact of newborn screening for SCID on the management of congenital athymia. Journal of Allergy and Clinical Immunology, 153(1), 330-334. https://doi.org/10.1016/j.jaci.2023.08.031

Vancouver

Howley E, Golwala Z, Buckland M, Barzaghi F, Ghosh S, Hackett S, et al. Impact of newborn screening for SCID on the management of congenital athymia. Journal of Allergy and Clinical Immunology. 2024;153(1):330-334. doi:10.1016/j.jaci.2023.08.031

BibTeX
@article{Howley2024,
  author = {Howley, Evey and Golwala, Zainab and Buckland, Matthew and Barzaghi, Federica and Ghosh, Sujal and Hackett, Scott and Hague, Rosie and Hauck, Fabian and Holzer, Ursula and Klocperk, Adam and Koskenvuo, Minna and Marcus, Nufar and Marzollo, Antonio and Pac, Malgorzata and Sinclair, Jan and Speckmann, Carsten and Soomann, Maarja and Speirs, Lynne and Suresh, Sneha and Taque, Sophie and van Montfrans, Joris and von Bernuth, Horst and Wainstein, Brynn K and Worth, Austen and Davies, E Graham and Kreins, Alexandra Y},
  title = {Impact of newborn screening for SCID on the management of congenital athymia},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2024},
  volume = {153},
  number = {1},
  pages = {330--334},
  doi = {10.1016/j.jaci.2023.08.031}
}
Kostenlos starten →